Stock News

Sivik Global Healthcare Boosted Clovis Oncology Com Stk (CLVS) Position; Pultegroup (PHM) Shorts Down By 19.32%

PulteGroup, Inc. (NYSE:PHM) Logo

Pultegroup Inc (NYSE:PHM) had a decrease of 19.32% in short interest. PHM’s SI was 18.09M shares in May as released by FINRA. Its down 19.32% from 22.42M shares previously. With 4.11M avg volume, 4 days are for Pultegroup Inc (NYSE:PHM)’s short sellers to cover PHM’s short positions. The SI to Pultegroup Inc’s float is 6.74%. The stock decreased 0.12% or $0.035 during the last trading session, reaching $29.875. About 2.11 million shares traded. PulteGroup, Inc. (NYSE:PHM) has risen 24.54% since May 21, 2017 and is uptrending. It has outperformed by 12.99% the S&P500.

Sivik Global Healthcare Llc increased Clovis Oncology Inc Com Stk (CLVS) stake by 16.67% reported in 2017Q4 SEC filing. Sivik Global Healthcare Llc acquired 5,000 shares as Clovis Oncology Inc Com Stk (CLVS)’s stock declined 18.56%. The Sivik Global Healthcare Llc holds 35,000 shares with $2.38 million value, up from 30,000 last quarter. Clovis Oncology Inc Com Stk now has $2.61 billion valuation. The stock decreased 0.69% or $0.345 during the last trading session, reaching $49.745. About 561,423 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 21.43% since May 21, 2017 and is downtrending. It has underperformed by 32.98% the S&P500.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.39, from 1.44 in 2017Q3. It worsened, as 35 investors sold CLVS shares while 69 reduced holdings. 31 funds opened positions while 78 raised stakes. 49.09 million shares or 3.43% more from 47.46 million shares in 2017Q3 were reported. Rice Hall James & Associates stated it has 147,650 shares. Proshare Advisors Limited Company reported 34,250 shares. Tiaa Cref Inv Limited Company has invested 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS). Lord Abbett Llc has 193,117 shares. Federated Invsts Pa holds 16,000 shares or 0% of its portfolio. Profund Advisors Ltd Liability Corp invested in 19,263 shares or 0.05% of the stock. Swiss Bancshares, Switzerland-based fund reported 79,050 shares. Geode Capital Mngmt Llc holds 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 436,518 shares. Voya Investment Management Ltd accumulated 0.06% or 433,999 shares. San Francisco Sentry Invest Gru (Ca) holds 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 400 shares. The Massachusetts-based Westfield Capital Mgmt LP has invested 0.26% in Clovis Oncology, Inc. (NASDAQ:CLVS). Hbk Investments Lp has 0.05% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 84,106 shares. Sphera Funds Management Limited invested 1.26% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). First Republic Mgmt reported 3,186 shares or 0% of all its holdings. Kazazian Asset Management Limited Liability Company holds 19,517 shares or 1.36% of its portfolio.

Sivik Global Healthcare Llc decreased Boston Scientific Corp Com Stk (NYSE:BSX) stake by 70,000 shares to 190,000 valued at $4.71M in 2017Q4. It also reduced Biogen Inc Com Stk (NASDAQ:BIIB) stake by 2,500 shares and now owns 20,000 shares. Valeant Pharmaceuticals Intern Com (NYSE:VRX) was reduced too.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 64 analyst reports since September 10, 2015 according to SRatingsIntel. The stock has “Buy” rating by SunTrust on Friday, April 6. WallachBeth Capital maintained the stock with “Hold” rating in Monday, May 9 report. The rating was initiated by Bank of America with “Buy” on Friday, January 27. The firm has “Neutral” rating given on Monday, November 16 by Piper Jaffray. Chardan Capital Markets initiated it with “Sell” rating and $15 target in Tuesday, October 25 report. The firm has “Buy” rating by WallachBeth Capital given on Thursday, September 10. The firm has “Buy” rating by Suntrust Robinson given on Friday, August 5. J.P. Morgan maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Wednesday, September 6 with “Buy” rating. Credit Suisse upgraded it to “Outperform” rating and $41 target in Wednesday, September 21 report. The company was upgraded on Tuesday, June 20 by Janney Capital.

Since December 15, 2017, it had 0 insider buys, and 7 insider sales for $1.64 million activity. $162,270 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) shares were sold by IVERS-READ GILLIAN C. $270,090 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) shares were sold by SPICKSCHEN THORLEF.

Another recent and important Clovis Oncology, Inc. (NASDAQ:CLVS) news was published by Seekingalpha.com which published an article titled: “Clovis May 2018 Update” on May 16, 2018.

PulteGroup, Inc., through its subsidiaries, engages primarily in the homebuilding business in the United States. The company has market cap of $8.53 billion. The firm is involved in the acquisition and development of land primarily for residential purposes; and the construction of housing on such land. It has a 20.7 P/E ratio. It offers various home designs, including single-family detached, townhouses, condominiums, and duplexes under the Centex, Pulte Homes, Del Webb, DiVosta Homes, and John Wieland Homes and Neighborhoods names.

Among 22 analysts covering PulteGroup (NYSE:PHM), 11 have Buy rating, 2 Sell and 9 Hold. Therefore 50% are positive. PulteGroup had 76 analyst reports since September 11, 2015 according to SRatingsIntel. As per Tuesday, September 26, the company rating was maintained by KeyBanc Capital Markets. The stock of PulteGroup, Inc. (NYSE:PHM) earned “Buy” rating by RBC Capital Markets on Sunday, August 20. Barclays Capital initiated it with “Overweight” rating and $21 target in Friday, January 6 report. The rating was maintained by KeyBanc Capital Markets with “Hold” on Tuesday, October 31. Bank of America maintained the stock with “Buy” rating in Wednesday, October 25 report. The company was maintained on Tuesday, August 22 by KeyBanc Capital Markets. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, January 27 report. The stock of PulteGroup, Inc. (NYSE:PHM) earned “Neutral” rating by Mizuho on Wednesday, October 25. Mizuho upgraded the stock to “Buy” rating in Thursday, January 18 report. As per Friday, October 21, the company rating was maintained by FBR Capital.

Since December 8, 2017, it had 1 buy, and 5 selling transactions for $5.40 million activity. OShaughnessy Robert sold $3.15M worth of PulteGroup, Inc. (NYSE:PHM) on Friday, December 8. $97,061 worth of PulteGroup, Inc. (NYSE:PHM) was bought by Hawaux Andre J on Thursday, May 10. SMITH HARMON D sold $1.62 million worth of stock. $430,384 worth of PulteGroup, Inc. (NYSE:PHM) shares were sold by GRISE CHERYL W. On Wednesday, February 21 the insider OLEARY PATRICK J sold $260,607.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *